Medical Oncology

MET+

Questions discussed in this category

With the approval of capmatinib, how would you approach a newly diagnosed metastatic NSCLC with MET Exon 14 skipping mutation?

1 Answer available

Aside from MET exon 14 skip mutations, are there other targetable MET mutations or fusions that you would consider for TKI therapy?

Would you reserve TKI for after standard of care chemotherapy and immunotherapy or consider earlier line of treatment?

1 Answer available

What would be your approach in a patient with MET amplification and PDL-1 80% expression?

Do you use crizotinib for first-line therapy?

1 Answer available

Do you consider MET amplification in your first-line treatment decisions for patients with metastatic NSCLC?

1 Answer available

Papers discussed in this category

Cancer discovery, 2015-08

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

Annals of oncology : official journal of the European Society for Medical Oncology, 2018-10-01

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Nature, 2014-07-31

Comprehensive molecular profiling of lung adenocarcinoma.

Cancer discovery, 2015-08

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Related Topics in Medical Oncology